We examined levels of phosphorylated ERK1/2 or DOCK2 in CLL cells that expressed ROR1 (ROR1Pos) versus CLL cells of the small subgroup of patients that did not (termed ROR1Neg). This evidence concerns the gene DOCK2 and B-cell chronic lymphocytic leukemia.